Email updates

Keep up to date with the latest news and content from BMC Clinical Pathology and BioMed Central.

Open Access Highly Accessed Research article

Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer

Andreea Nistor1, Peter H Watson1, Norman Pettigrew2, Karim Tabiti3, Angelika Dawson4 and Yvonne Myal15*

Author affiliations

1 Department of Pathology, University of Manitoba, 770 Bannatyne Ave., Winnipeg, Manitoba R3E 0W3, Canada

2 Department of Pathology, Immunopathology Laboratory, Health Sciences Centre, 820 Sherbrook St., Winnipeg, Manitoba R3A 1A9, Canada

3 Head Alliance Management Oncology, Clinical Genomics, Roche diagnostics GmBH, Nonnenwaldstr. 2, D-82372 Penzberg, Germany

4 Department of Biochemistry & Medical Genetics, University of Manitoba, 770 Bannatyne Ave., Winnipeg, Manitoba R3E 0W3 and the Cytogenetics Laboratory, Health Sciences Centre 820 Sherbrook St., Winnipeg, Manitoba R3A 1A9, Canada

5 Molecular Diagnostic Pathology Laboratory, Department of Pathology, Health Sciences Centre, 820 Sherbrook St., Winnipeg, Manitoba R3A 1A9, Canada

For all author emails, please log on.

Citation and License

BMC Clinical Pathology 2006, 6:2  doi:10.1186/1472-6890-6-2

Published: 18 January 2006

Abstract

Background

The clinical benefit of determining the status of HER-2/neu amplification in breast cancer patients is well accepted. Although immunohistochemistry (IHC) is the most frequently used method to assess the over-expression of HER-2 protein, fluorescent in-situ hybridization (FISH) is recognized as the "gold standard" for the determining of HER-2/neu status. The greatest discordance between the two methods occurs among breast tumors that receive an indeterminate IHC score of 2+. More recently, a real-time polymerase chain reaction (PCR) assay using the LightCycler® has been developed for quantifying HER-2/neu gene amplification. In this study, we evaluated the sensitivity and specificity of a commercially available LightCycler assay as it compares to FISH. To determine whether this assay provides an accurate alternative for the determination of HER-2/neu status, we focused primarily on tumors that were deemed indeterminate or borderline status by IHC.

Methods

Thirty-nine breast tumors receiving an IHC score of 2+ were evaluated by both FISH and LightCycler® technologies in order to determine whether quantitative real-time PCR provides an accurate alternative for the determination of HER-2/neu status.

Results

We found a high concordance (92%) between FISH and real-time PCR results. We also observed that 10% of these tumors were positive for gene amplification by both FISH and real-time PCR.

Conclusion

The data show that the results obtained for the gene amplification of HER-2/neu by real-time PCR on the LightCycler® instrument is comparable to results obtained by FISH. These results therefore suggest that real-time PCR analysis, using the LightCycler®, is a viable alternative to FISH for reassessing breast tumors which receive an IHC score of 2+, and that a combined IHC and real-time PCR approach for the determination of HER-2 status in breast cancer patients may be an effective and efficient strategy.